Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Sanofi
 More »

  • Sanofi Presents Encouraging Phase III Data for Myelofibrosis...
    Sanofi today announced that its randomized, double-blind, placebo-controlled Phase III ... Roychowdhury, M.D., svp and head, Sanofi Oncology, said in a statement. "Since ...
    5-17-2013
  • Biotechs Need to Walk the Walk on Drug Value
    ... & Johnson, Lilly, Pfizer, Roche, and Sanofi-created TransCelerate BioPharma to speed ... Mitsubishi Tanabe, Novartis, Pfizer, and Sanofi-in developing the DILIsym(tm) predictive ...
    5-15-2013
  • Companion Diagnostics: 52 Pick-Up
    ... Financial terms not disclosed. HTG Molecular Diagnostics and Sanofi Agreement announced ... help identify patients most likely to respond to a new Sanofi investigational cancer drug. ...
    5-9-2013
  • Regeneron Gains Full Rights to Ophthalmology Antibodies from...
    at the company's labs, but previously included in its antibody collaboration with Sanofi. ... For the PDGF antibodies, Regeneron agreed to pay Sanofi $10 million up front, up to $40 ...
    5-3-2013
  • Critical Tools for Oligo Characterization
    The certificate allows the company to manufacture oligonucleotide active pharmaceutical ingredients. BioSpring has entered a commercial manufacturing agreement with Sanofi for ...
    5-1-2013
  • NextBio, Sanofi Team Up to Incorporate Omics Data into R&D
    NextBio and Sanofi are teaming up to incorporate omics and clinical data into the latter ... Financial terms of the agreement were not disclosed. "Sanofi has long used NextBio as an ...
    4-30-2013
  • OBT Joins Boehringer Ingelheim in Cancer Drug Collaboration
    with Seattle Genetics, Medarex (since acquired by Bristol-Myers Squibb), Amgen, Biosite (now Alere), and BioWa, as well as development alliances with Sanofi and Menarini. ...
    4-29-2013
  • GEN | Biolinks
    ... Saint-Gobain Performance Plastics Sandoz Sandoz Sangamo BioSciences SaniSure Sanofi Sanofi Aventis SARSTEDT Sartorius Stedim Biotech SAW Instruments Science Foundation ...
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    ... & Johnson, Lilly, Pfizer, Roche, and Sanofi-created TransCelerate BioPharma to speed ... Mitsubishi Tanabe, Novartis , Pfizer, and Sanofi-in developing the DILIsym(tm) predictive ...
    4-22-2013
  • Biosimilars: 10 Drugs to Watch
    ... of insulin analog Humalog (Eli Lilly) Glargine: Biocon and Mylan on February 14 announced a strategic collaboration to develop a biosimilar to the insulin analog Lantus (Sanofi)
    4-22-2013
  • People in the News
    Most recently, Taylor was vp, global clinical trial management at Pfizer. He also served as global head of outsourcing management at Sanofi-Aventis. Steve Butcher joined CoCo ...
    4-15-2013
  • CEO Perks
    ... Viehbacher Sanofi, CEO Perks and "other" compensation: Reported in 2012 Annual Report as "Benefits in kind," €4,051 ($5,310), which "relates principally to a company car." ...
    4-12-2013
  • Yeast Strain Rises to Fight Malaria
    Sanofi and nonprofit drug developer OneWorld Health said today they launched large-scale ... Sanofi and OneWorld Health, a drug-development affiliate of nonprofit PATH, said they ...
    4-11-2013
  • Sanofi and Pieris Broaden Protein Drug Deal
    Sanofi and Pieris agreed to expand their ongoing discovery and development partnership to ... Pieris to an up-front payment from Sanofi and committed research funding as well as ...
    4-10-2013
  • Bird Flu Back Again?
    ... And dedicated manufacturing of a vaccine against H7N9 vaccine could cause shortages of vaccine against normal season flu. Vaccine manufacturers include Sanofi Pasteur, the world's ...
    4-9-2013
  • More »

    Journal Articles

  • Study on the Dosing Accuracy of Commonly Used Disposable Insulin...
    Meike Krzywon, Thomas van der Burg, Uwe Fuhr, Manfred Schubert-Zsilavecz, Mona Abdel-Tawab
    Diabetes Technology & Therapeutics
    Materials and Methods: In total, 15 previously unused insulin pens from two lots of each pen type (SoloSTAR® [sanofi-aventis, Paris, France], FlexPen® [Novo Nordisk A/S, ...
  • Rationale, Design, and Baseline Data of the Insulin Glargine...
    Sanne G.H.A. Swinnen, Frank J. Snoek, Marie-Paule Dain, J. Hans DeVries, Joost B.L. Hoekstra, Frits Holleman
    Diabetes Technology & Therapeutics
    Diabetes Technology & Therapeutics Abstract Objective: To discuss the design and baseline data of the Lantus® (sanofi-aventis, Paris, France) versus Levemir® (Novo Nordisk A/S, ...
  • Dose Accuracy of SoloSTAR and FlexPen as Assessed in a Clinical...
    Arnd Friedrichs
    Diabetes Technology & Therapeutics
    Diabetes Technology & Therapeutics Abstract Aims: This study aimed to compare the accuracy of SoloSTAR® (sanofi-aventis, Paris, France) and FlexPen® (Novo Nordisk, Bagsvaerd, ...
  • The Best Insulin Injection Pen Device for Caregivers: Results...
    Fumiatsu Yakushiji, Hiroshi Fujita, Yoshiyasu Terayama, Mutsuko Yasuda, Kaoru Nagasawa, Masako Shimojo, Ken Taniguchi, Kazuhiko Fujiki, Jyunji Tomiyama, Hiroyuki Kinoshita
    Diabetes Technology & Therapeutics
    Methods: We evaluated five devices-OptiClik® (Sanofi-aventis, Paris, France), SoloStar® (Sanofi-aventis), MirioPen® without an antiskid tool (Eli Lilly and Co., Indianapolis, ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll